CYDY - CytoDyn to release CD12 trial data on March 8

CytoDyn (CYDY) will release the CD12 clinical trial data via Form 8-K after the investment community webcast on Monday, March 8, 2021.The Company’s recently completed CD12 Phase 3 trial evaluated leronlimab in severe-to-critical COVID-19.Key findings are as follows:Survival benefit: There was a 24% reduction in all-cause mortality (primary endpoint) in the leronlimab vs. placebo for invasive mechanical ventilated critically ill patients.Shortened time to recovery: The average length of hospital stay was lower in leronlimab group compared to placebo/SoC group with a statistically significant p-value of 0.0050.Discharge alive: Leronlimab-receiving patients demonstrated an improved probability of "discharged alive" at Day 28 (28% vs. 11%), a 166% better rate than in the placebo group.As a consequence of an imbalance among enrolled patients over 65 years of age and under 65, an “age adjustment” analysis was performed, which was reported earlier.Also, CytoDyn is on its path to approval of leronlimab in U.S., U.K., and

For further details see:

CytoDyn to release CD12 trial data on March 8